Blog

The Future of Phase I Oncology Studies

July 10, 2019

Phase I studies in oncology pose challenges unlike any other early phase study. Most phase I studies begin with healthy volunteers, but because of the unique nature of the trial…

Blog

The Noble Pursuit of Investigator-Initiated Research

June 19, 2019

Stem cell clinics with unproven treatments are on the rise in the US. Learn how the FDA is working to bring new stem cell therapies under federal oversight.

Blog

The Challenge of Unproven Regenerative Stem Cell Therapies

June 5, 2019

Stem cell clinics with unproven treatments are on the rise in the US. Learn how the FDA is working to bring new stem cell therapies under federal oversight.

Blog

Six Key GDPR Questions to Review

May 1, 2019

Questions still remain about GDPR and its applications. Have you considered these six key questions to ask within your organization?

Blog

Can Ethics Review Catch Up to the CBD Craze?

April 22, 2019

CBD, a non-psychoactive cannabinoid, is experiencing a massive surge in popularity, but clinical research lags behind in verifying effective uses.

Blog

Quorum/Kinetiq Acquisition & Integration:
What You Need to Know

March 14, 2019

On March 5, 2019, Advarra announced its acquisition of Quorum Review IRB and Kinetiq, the research and technology consulting division of Quorum. We’ve assembled this FAQ to address some of…

Blog

After the Compliance Date: Revised Common Rule FAQs (Or: Why We Cancelled Our February Webinar)

February 22, 2019

The bad news is we cancelled our webinar on the revised Common Rule. The good news? We cancelled it because it seems the revised Common Rule implementation and transition have…

Blog

Informed Consent Changes in the Revised Common Rule

January 18, 2019

Many of the revised Common Rule’s changes aim to make informed consent more meaningful, so that research subjects have the...

Blog

Do I Need to Comply With the Revised Common Rule?

January 18, 2019

Most requirements of the revised Common Rule go into effect January 21, 2019*. While many US researchers are aware of...

Blog

Reporting to the IRB: Serious Adverse Events (SAEs) in Drug Studies

December 14, 2018

At Advarra, we often get questions about exactly what events should be reported to the IRB. We understand that “reportable...